[
    [
        {
            "time": "2023-10-01",
            "original_text": "AbbVie Declares Quarterly Dividend",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Quarterly",
                    "Dividend"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Declares Quarterly Dividend",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 10
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Endometriosis: an invisible disease affecting half a million Canadians",
            "features": {
                "keywords": [
                    "Endometriosis",
                    "invisible disease",
                    "Canadians"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Endometriosis: an invisible disease affecting half a million Canadians",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 1,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "U.K. trial sparks interest in dexamethasone’s potential as a treatment for severely ill COVID-19 patients",
            "features": {
                "keywords": [
                    "U.K.",
                    "trial",
                    "dexamethasone",
                    "COVID-19",
                    "treatment"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "U.K. trial sparks interest in dexamethasone’s potential as a treatment for severely ill COVID-19 patients",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]